UB Paderborn / Katalog / Suche / in CDI

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

Clinical cancer research, 2017-08, Vol.23 (15), p.4335-4346

2017

Link zum Volltext

Verfügbarkeit prüfen

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

International journal of molecular sciences, 2021-05, Vol.22 (11), p.5570

2021

Link zum Volltext

Verfügbarkeit prüfen

Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis

JNCI : Journal of the National Cancer Institute, 2013-06, Vol.105 (12), p.908-916

2013

Link zum Volltext

Verfügbarkeit prüfen

Improved methods for testing antiresorptive compounds in human osteoclast cultures

Journal of bone and mineral metabolism, 2009-01, Vol.27 (1), p.105-109

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract 364: Validation of human osteoclast cultures for studying the mode-of-action and identification of new compounds with the potential of inhibiting the vicious cycle in osteolytic bone metastases

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.364-364

2016

Link zum Volltext

Verfügbarkeit prüfen

Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption

Clinical laboratory (Heidelberg), 2006, Vol.52 (9-10), p.499

2006

Link zum Volltext

Verfügbarkeit prüfen

In vitro model of bone to facilitate measurement of adhesion forces and super-resolution imaging of osteoclasts

Scientific reports, 2016-03, Vol.6 (1), p.22585-22585, Article 22585

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 640: New models of breast and lung cancer bone metastases for preclinical efficacy testing

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.640-640

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 381: PI3K inhibitor BAY 1082439 and radium-223 dichloride decrease tumor burden and tumor-induced bone formation in an established bone metastatic prostate cancer model in mice

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.381-381

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.2759-2759

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1806: Novel preclinical orthotopic and bone metastasis TNBC models for assessment of immunotherapy and chemotherapy responses

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1806-1806

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2007-2007

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase

Archives of biochemistry and biophysics, 2006-05, Vol.449 (1), p.1-7

2006

Link zum Volltext

Verfügbarkeit prüfen

Differences in knee osteoarthritis between surgically and chemically induced rat models

Bone Reports, 2022-05, Vol.16, p.101452, Article 101452

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1624: Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1624-1624

2022

Link zum Volltext

Verfügbarkeit prüfen

Specificity and clinical performance of two commercial TRACP 5b immunoassays

Clinical laboratory (Heidelberg), 2009, Vol.55 (5-6), p.223

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2481: Human osteoclast assays for studying the effects of bone metastasis treatments with different mechanisms of action

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2481-2481

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 49: Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.49-49

2023

Link zum Volltext

Verfügbarkeit prüfen

Differences between the effects of anti-catabolic zoledronate and anabolic teriparatide treatments on bone in adult ovariectomized rats

Bone Reports, 2022-05, Vol.16, p.101449, Article 101449

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract A151: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies against HER2-positive breast cancer

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.A151-A151

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4207: Selective drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4207-4207

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 5202: Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5202-5202

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3838: Drug sensitivity profile of 5TGM1 murine multiple myeloma cell line emphasizes the translational potential of the syngeneic in vivo model

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3838-3838

2017

Link zum Volltext

Verfügbarkeit prüfen

The Combination of Radium-223 Dichloride and Bortezomib Effectively Reduces Tumor Burden and Lesion Area in the Syngeneic, Systemic 5TGM1 Multiple Myeloma Mouse Model

Blood, 2017-12, Vol.130, p.1802-1802

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 786: Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.786-786

2015

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

Survival Benefit With Radium-223 Dichloride in a Mouse Model of Breast Cancer Bone Metastasis

Improved methods for testing antiresorptive compounds in human osteoclast cultures

Abstract 364: Validation of human osteoclast cultures for studying the mode-of-action and identification of new compounds with the potential of inhibiting the vicious cycle in osteolytic bone metastases

Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption

In vitro model of bone to facilitate measurement of adhesion forces and super-resolution imaging of osteoclasts

Abstract 640: New models of breast and lung cancer bone metastases for preclinical efficacy testing

Abstract 381: PI3K inhibitor BAY 1082439 and radium-223 dichloride decrease tumor burden and tumor-induced bone formation in an established bone metastatic prostate cancer model in mice

Abstract 2759: Immune cell killing assay for analyzing the effects of immunomodulating agents in vitro

Abstract 1806: Novel preclinical orthotopic and bone metastasis TNBC models for assessment of immunotherapy and chemotherapy responses

Abstract 2007: Validation of a preclinical model for bone metastatic triple negative breast cancer

Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase

Differences in knee osteoarthritis between surgically and chemically induced rat models

Abstract 1624: Immune cell killing assay for measuring the effects of immunomodulating agents in lung cancer cells in vitro

Specificity and clinical performance of two commercial TRACP 5b immunoassays

Abstract 2481: Human osteoclast assays for studying the effects of bone metastasis treatments with different mechanisms of action

Abstract 49: Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer

Differences between the effects of anti-catabolic zoledronate and anabolic teriparatide treatments on bone in adult ovariectomized rats

Abstract A151: Drug sensitivity profiling of BT-474 breast cancer cell line for identification of novel therapies against HER2-positive breast cancer

Abstract 4207: Selective drug sensitivity score (DSS) for indolent and aggressive prostate cancer cell lines

Abstract 5202: Additive benefits of radium-223 dichloride and bortezomib combination in a syngeneic 5TGM1 multiple myeloma mouse model

Abstract 3838: Drug sensitivity profile of 5TGM1 murine multiple myeloma cell line emphasizes the translational potential of the syngeneic in vivo model

The Combination of Radium-223 Dichloride and Bortezomib Effectively Reduces Tumor Burden and Lesion Area in the Syngeneic, Systemic 5TGM1 Multiple Myeloma Mouse Model

Abstract 786: Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model

Suchergebnisse filtern